US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
SNDK
$1,719.99
▲+0.00%
NVDA
$233.95
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
MSTR
$160.01
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
SNDK
$1,719.99
▲+0.00%
NVDA
$233.95
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
MSTR
$160.01
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
2.880
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
Lexaria Bioscience Comments on Study Examining Cannabinoids and SARS-CoV-2
↗
January 19, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience (NASDAQ: LEXX), a...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Comments on Study Examining Cannabinoids and SARS-CoV-2
January 19, 2022
Via
Investor Brand Network
Topics
Cannabis
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Comments Regarding Study Examining Cannabinoids and SARS-CoV-2
January 18, 2022
Via
Investor Brand Network
Topics
Cannabis
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Comments Regarding Study Examining Cannabinoids and SARS-CoV-2
January 18, 2022
Via
CannabisNewsWire
Topics
Cannabis
Lexaria Bioscience Leveraging DehydraTECH(TM) for More Effective Oral Medicine
↗
January 18, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Leveraging DehydraTECH(TM) for More Effective Oral Medicine
January 18, 2022
Via
Investor Brand Network
Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
January 18, 2022
"Cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2" KELOWNA, BC / ACCESSWIRE / January 18, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company"...
From
Lexaria Bioscience Corp.
Via
AccessWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) to Deliver More Effective Oral Medicine
January 14, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) to Deliver More Effective Oral Medicine
January 14, 2022
Via
Investor Brand Network
After a Successful 2021, Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off 2022 With New Media Strategy, Plans for Clinical Study Advancements
January 14, 2022
Via
Investor Brand Network
Lexaria Bioscience Celebrates Productive Year for Blood Pressure Drug Solution
↗
January 12, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience’s ongoing...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Celebrates Productive Year for Blood Pressure Drug Solution
January 12, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Celebrates Productive Year for Blood Pressure Drug Solution with Eye on Advancing Clinical Studies in 2022
January 12, 2022
Via
Investor Brand Network
Lexaria Bioscience (NASDAQ: LEXX) Receives Independent Review Board Approval for Human Study
↗
January 11, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria has received approval from the...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Receives Independent Review Board Approval for Human Study
January 11, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Independent Review Board Approval for Its Most Ambitious, Comprehensive Human Study Yet
January 10, 2022
Via
Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
↗
January 07, 2022
Gainers ContraFect (NASDAQ:CFRX) stock mo...
Via
Benzinga
Lexaria Bioscience Increases Investor Visibility with SRAX
↗
January 07, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The strategic move to incorporate...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Increases Investor Visibility with SRAX (NASDAQ: SRAX)
January 07, 2022
Via
Investor Brand Network
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
January 06, 2022
Gainers ContraFect (NASDAQ:CFRX) stock in...
Via
Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Increases Investor Visibility with SRAX Inc. (NASDAQ: SRAX)
January 06, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals One Drug Class at a Time
January 04, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals One Drug Class at a Time
January 04, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria Bioscience Announces Approval from Independent Review for DehydraTECH-CBD Study
↗
December 30, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has received Independent Review Board (“IRB”) approval for its planned DehydraTECH-...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Announces Approval from Independent Review for DehydraTECH-CBD Study
December 30, 2021
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Approval from Independent Review Board for DehydraTECH-CBD Human Clinical Study
December 29, 2021
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Approval from Independent Review Board for DehydraTECH-CBD Human Clinical Study
December 29, 2021
Via
Investor Brand Network
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
December 29, 2021
• Dosing is expected to begin by April, 2022 KELOWNA, BC / ACCESSWIRE / December 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Bioscience Expects Study Results to Show Patented Tech's Value in Treating Hypertension
↗
December 28, 2021
Lexaria Bioscience is preparing to file an Investigational New Drug application with the U.S. Food and Drug Administration for its patented technology’s use in treating...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Expects Study Results to Show Patented Tech’s Value in Treating Hypertension
December 28, 2021
Via
Investor Brand Network
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
